Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Dx Firm Metamark Genetics Raises $22M

This article has been updated with additional information from a company statement.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer diagnostics startup Metamark Genetics has raised about $22 million in a Series B round of financing, it disclosed in a document filed with the US Securities and Exchange Commission.

The company is targeting about $42 million in total, it said. Among the participants in the round were directors and executives at the Cambridge, Mass.-based firm, which said that it intends the offering to last more than one year. It is not related to a business combination transaction, such as a merger, acquisition, or exchange offer, Metamark said in its filing.

Metamark said in a statement released today that the lead investor in the round has an obligation to purchase up to an aggregate of $8 million of additional preferred stock.

Proceeds will be used to expand Metamark's research and development efforts and clinical testing infrastructure, and establish its commercial organization, the firm said.

Metamark was founded in 2007 and develops diagnostic tests to "enable personalized treatment planning for cancer patients, improved outcomes, and reduced healthcare costs," according to its website. Its lead platform is the Prognosis Determinants system, based on research in melanoma by Lynda Chin at the Dana-Farber Cancer Institute and Harvard Medical School. Chin is also a director of Metamark.

Using the platform, Metamark said it has identified and validated functionally active genetic determinants of metastasis "critical to the progression of a broad spectrum of tumor types." The company is developing diagnostic assays based on its discoveries.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.